Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 11/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.58 |
| ▸ | CDK2 | P24941 | 6/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7756995 | 0.84 | MAPT (0.68) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL1250879 | 0.80 | CDK5 (0.54) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL27591327 | 0.78 | CDK5 (0.85) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL5725669 | 0.77 | CDK5 (0.49) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL1250875 | 0.73 | CDK5 (1.00) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL13675041 | 0.72 | GSK3A (0.54) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL13534527 | 0.70 | ALDH1A1 (0.73) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL4483238 | 0.69 | CDK5 (1.00) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL1248181 | 0.68 | CDK2 (1.00) | CDK5CDK5R1CDK2GSK3BCCNA2 | |
| SCHEMBL29793056 | 0.67 | KIF11 (0.60) | MAPTLMNAKMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | claimed |
| CN-101380319-A | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | ALCON INC (CH) | 2009-03-11 | — | — | CN | claimed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | claimed |
| CN-1561393-A | Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma | ALCON INC (CH) | 2005-01-05 | — | — | CN | claimed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-2281560-A1 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy | Alcon, Inc. (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | disclosed |
| US-7598288-B2 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | ALCON, INC. (CH) | 2009-10-06 | — | — | US | disclosed |
| CN-101380319-A | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | ALCON INC (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | disclosed |
| CN-1561393-A | Inhibitors of glycogen synthase kinase-3 (GSK-3) for the treatment of glaucoma | ALCON INC (CH) | 2005-01-05 | — | — | CN | disclosed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | CDK5 367/4885CDK5R1 778/4885CDK2 1208/4885 |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | GSK3B, GSK3A, GSKIP | CDK5 367/4885CDK5R1 778/4885CDK2 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.